Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could saliva hold the key to understanding gum disease?

NCT ID NCT07755228

Knowledge-focused Sponsor: Medipol University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This observational study looks at whether two proteins found in saliva—Gasdermin E and Granzyme B—are present in different amounts in people with periodontitis (a severe form of gum disease) compared to those with healthy gums. Researchers will collect saliva samples and measure gum health in about 46 adults aged 18 to 65. No treatment is given; the goal is to better understand the inflammation involved in periodontitis and possibly identify new markers for the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If certain proteins in saliva are found to differ between people with and without periodontitis, they could become markers for diagnosing or monitoring the disease.
What could go wrong
This is a small observational study, so it cannot prove cause and effect. The findings may not apply to all cases of periodontitis, and more research would be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

46 people

The number who actually took part.

Started

Jun 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of 40 systemically healthy adults aged 18 to 65 years who present to the Department of Periodontology at Istanbul Medipol University Faculty of Dentistry. Based on the 2017 AAP/EFP classification, 23 participants diagnosed with generalized Stage III Grade B periodontitis will constitute the periodontitis group, and 23 participants with an intact and clinically healthy periodontium will constitute the control group.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals aged 18 to 65 years * Presence of at least 20 natural teeth, excluding third molars * Being systemically healthy * Provision of written informed consent * For the periodontitis group, diagnosis of generalized Stage III Grade B periodontitis according to the 2017 AAP/EFP classification * Clinical attachment loss of at least 2 mm at two or more non-adjacent teeth for the periodontitis group * Interdental clinical attachment loss of at least 5 mm and periodontitis-related loss of no more than four teeth for Stage III periodontitis * A radiographic bone loss-to-age ratio between 0.25 and 1.00 for Grade B periodontitis * For the healthy control group, an intact periodontium, probing depth of 3 mm or less, and bleeding on probing at less than 10% of sites Exclusion Criteria: * Use of antibiotics, antimicrobial agents, nonsteroidal anti-inflammatory drugs, steroids, immunosuppressants, beta-blockers, calcium channel blockers, anticoagulants, or hormonal contraceptives within the previous 3 months * Periodontal treatment within the previous 6 months * Surgical periodontal treatment within the previous 12 months * Current smoking * Pregnancy or breastfeeding * Presence of any neurological, autoimmune, metabolic, inflammatory, or other systemic condition that could affect the immune response * Use of an orthodontic appliance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Periodontal health are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Periodontal health Periodontitis

Contacts and locations

Locations

  • Istanbul Medipol University

    Istanbul, 34810, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.